🔎 Trials Near Me

Início › Câncer de Pulmão de Não Pequenas Células › Connecticut

Ensaios clínicos de Câncer de Pulmão de Não Pequenas Células em Connecticut

55 estudos para Câncer de Pulmão de Não Pequenas Células estão buscando participantes em locais em Connecticut.

Cidades em Connecticut

Texto oficial do estudo (Inglês)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Smilow Cancer Hospital-Derby Care Center, Derby
  • Smilow Cancer Hospital Care Center-Fairfield, Fairfield
  • Smilow Cancer Hospital Care Center at Greenwich, Greenwich
  • e mais 9
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 5 de out. de 2026 · NCT04267848

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Yale Cancer Center, New Haven
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04585750

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  • Yale University School of Medicine ( Site 0201), New Haven
  • Eastern CT Hematology & Oncology Associates ( Site 0202), Norwich
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06623422

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  • Eastern Connecticut Hematology and Oncology Associates, Norwich
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06472245

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #62, New Haven
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT05176483

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

  • University of Connecticut Health Center ( Site 0130), Farmington
  • Stamford Hospital ( Site 0126), Stamford
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07190248

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

  • Smilow Cancer Center at Yale-New Haven ( Site 3253), New Haven
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07513376

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • Yale Cancer Center, New Haven
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06172478

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • Hartford HealthCare - Avon, Avon
  • Hartford Hospital, Hartford
  • Hartford HealthCare - Manchester, Manchester
  • e mais 2
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06498635

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

  • Smilow Cancer Hospital - Yale New Haven Health, New Haven
  • Yale - New Haven Hospital - Yale Cancer Center, New Haven
  • Smilow Cancer Hospital Phase 1 Unit, New Haven
  • e mais 1
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07090499

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

  • Yale Cancer Center, New Haven
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT07578571

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  • Yale University, Smillow Cancer Center, New Haven
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT06881784

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

  • Yale University, New Haven
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06667908

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

  • Kivu Trial Site, New Have
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT07229313

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  • Hartford Hospital (HH), Hartford
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06890598

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

  • Research Site, New Haven
RecrutandoFase 2
Idades de 18 a 95 · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT05061550

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

  • Yale University, Yale Cancer Center, New Haven
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT05983432

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

  • Research Site, West Haven
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT06692738

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

  • Yale Cancer Center, New Haven
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07349537

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  • Yale University School of Medicine - Yale Cancer Center, New Haven
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT05786924

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  • Eastern Connecticut Hematology and Oncology Associates, Norwich
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT04613596

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

  • Yale Cancer Center, New Haven
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT06303505

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

  • Yale Cancer Center, New Haven
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 10 de set. de 2026 · NCT04302025

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

  • Yale Cancer Center, New Haven
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 9 de set. de 2026 · NCT07166601

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • Yale University School of Medicine, New Haven
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT06119581

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

  • Yale Cancer Center, New Haven
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 4 de set. de 2026 · NCT07361562

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

  • Yale Cancer Center, New Haven
  • Norwalk Hospital, Norwalk
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT06343402

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

  • Hartford Healthcare, Hartford
  • Yale University, New Haven
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT07070232

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

  • Research Site, New Haven
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 26 de ago. de 2026 · NCT06350097

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

  • Yale University, New Haven
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 5 de ago. de 2026 · NCT07111520

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

  • Yale University - Cancer Center, New Haven
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 5 de ago. de 2026 · NCT06706076

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

  • Eastern Connecticut Hematology and Oncology Associates, Norwich
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 3 de ago. de 2026 · NCT07397338

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

  • Yale New Haven Hospital, Yale Cancer Center, New Haven
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 21 de jul. de 2026 · NCT05098132

Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer

  • Smilow Cancer Hospital Care Center at Greenwich, Greenwich
  • Smilow Cancer Hospital Care Center - Guilford, Guilford
  • Smilow Cancer Hospital - Hamden Care Center, Hamden
  • e mais 3
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 17 de jun. de 2026 · NCT04210492

Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.